NEW YORK, Jan. 10, 2006 (PRIMEZONE) -- Taglich Brothers, Inc. announces it has initiated coverage of CardioTech International, Inc. (AMEX:CTE).
CardioTech International, Inc. is a medical device company that develops, manufactures and sells advanced products for the treatment of cardiovascular disease. CardioPass is the Company's proprietary, synthetic coronary artery bypass graft and CardioTech has partnered to develop a drug-eluting stent. The Company generates revenues from sales of advanced medical devices and disposables used during cardiopulmonary bypass procedures, as well as from contracted product design and development services.
The complete 20-page report is available at www.taglichbrothers.com.
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, Robert Taglich, Managing Director, owns 3,000 shares of CTE. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company within the last three years. The company paid an engagement fee of $5,000 (USD) on October 2005, and upon publication will pay a monthly monetary fee of $1,500 (USD) to Taglich Brothers, Inc., for the creation and dissemination of research reports.